Buy Travoprost Online
Travoprost, sold under the brand name Travatan among others.
| Active substance: | Travoprost |
| U.S. Brand: | Travatan |
| Indian Brand: | Lupitros |
| Mfd by: |  |
| Strength: | 0.004% |
| Form release: | 3ml bottle |
| Shipping time: | 7 – 21 days |
| Best price: | 12.00 USD |
| Order: | through request form |
Travoprost, is medications used to treat high pressure inside the eye including glaucoma and ocular hypertension (a condition which causes increased pressure in the eye). Travoprost is in a class of medications called prostaglandin analogs. It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye.
Specifically it is used for open angle glaucoma when other agents are not sufficient. It is used as an eye drop. Effects generally occur within 2 hours. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.
To instill the eye drops, follow these steps:
- Wash your hands thoroughly with soap and water.
- Check the dropper tip to make sure that it is not chipped or cracked.
- Avoid touching the dropper tip against your eye or anything else; eye drops and droppers must be kept clean.
- While tilting your head back, pull down the lower lid of your eye with your index finger to form a pocket.
- Hold the dropper (tip down) with the other hand, as close to the eye as possible without touching it.
- Brace the remaining fingers of that hand against your face.
- While looking up, gently squeeze the dropper so that a single drop falls into the pocket made by the lower eyelid. Remove your index finger from the lower eyelid.
- Close your eye for 2 to 3 minutes and tip your head down as though looking at the floor. Try not to blink or squeeze your eyelids.
- Place a finger on the tear duct and apply gentle pressure.
- Wipe any excess liquid from your face with a tissue.
- If you are to use more than one drop in the same eye, wait at least 5 minutes before instilling the next drop.
- Replace and tighten the cap on the dropper bottle. Do not wipe or rinse the dropper tip.
- Wash your hands to remove any medication.
- eye pain or irritation
- blurred vision
- dry eyes
- eye tearing
- headache
Travoprost eye drops may change the color of your eye (to brown) and darken the skin around the eye. It may also cause your eyelashes to grow longer and thicker and darken in color. These changes usually occur slowly, but they may be permanent. If you use travoprost eye drops in only one eye, you should know that there may be a difference between your eyes after using travoprost eye drops. Call your doctor if you notice these changes.
Ocular Therapeutix gave itself a low bar to clear in the latest phase III study of OTX-TP, pitting the glaucoma project against placebo rather than an active comparator – but even that was not low enough. The trial failed to show a decrease in intraocular pressure with OTX-TP, an eye insert that delivers travoprost, versus placebo, across the 12-week study. Despite the failure, Ocular still hopes the project has a future, highlighting an analysis of intraocular pressure at individual timepoints that it said showed a significant benefit with OTX-TP on eight of nine occasions. Still, as the primary endpoint was not hit, these findings can only be considered exploratory. And OTX-TP’s effect appeared to wane over time, raising questions about the company’s sustained delivery approach. Ocular will take the latest data to the FDA but even if the agency decides to be lenient, OTX-TP will struggle to find a place in the market – the project previously failed to beat an active comparator, generic timolol. Investors, who had hoped OTX-TP would fare better against placebo, sent Ocular’s stock down 17% in premarket trading today. Today’s failure might also bode ill for Ocular’s next project, OTX-TIC, a bioresorbable travoprost implant that is in phase I.
| Ocular Therapeutix’s clinical-stage pipeline | |||
|---|---|---|---|
| Project | Description | Indication | Status |
| OTX-TP | Travoprost insert | Glaucoma and ocular hypertension | Failed phase III |
| OTX-TIC | Travoprost implant | Glaucoma and ocular hypertension | Phase I |
| OTX-TKI | Tyrosine kinase inhibitor implant | Wet AMD, DME, RVO | Phase I |
| AMD: Age-related macular degeneration, DME: Diabetic macular edema, RVO: Retinal vein occlusion. Source: EvaluatePharma, company website. | |||
Ocular Therapeutix’s latest drug/device — for glaucoma — has flopped in its Phase III study, failing the primary endpoint to significantly reduce intraocular pressure versus placebo.
The treatment, OTX-TP, is an intracanalicular insert designed to deliver a formulation of the drug travoprost with an effect up to 90 days, which Ocular says can solve the adherence issues seen with daily eye drop regimens that patients are typically prescribed.
Investigators tracked the change in IOP from baseline in 554 patients in the study over several months, taking measurements at nine time points: 8 am, 10 am and 4 pm on one day at 2, 6 and 12 weeks following insertion. The first six sessions, the company says, were just fine — recording statistically significant reductions of IOP with p-values as low as 0.001 — but the seventh threw them off.
In fact, as they lay out in a table, that’s the only time point where OTX-TP did not achieve a statistically significant reduction of IOP compared to placebo.
“We are encouraged by the results of this trial which shows OTX-TP’s ability to lower IOP out to 12 weeks with a single insert using this novel dosage form,” said chief medical officer Michael Goldstein, adding that his team will now take the data to the FDA to determine next steps.
Ocular’s relationship with the FDA, though, has not always been smooth. Its first drug/device eye treatment, Dextenza, was rejected twice before nabbing an approval, forcing a restructuring that claimed a fifth of its staff. The company finally managed to sort out the manufacturing issue and began marketing the therapy for post-surgical pain late last year.
Some investors aren’t sticking around. Shares $OCUL are still down 12% (to $3.37) in pre-market trading, following the announcement at Monday close.
AUTHOR & ASSOCIATE EDITOR: Amber Tong
amber@endpointsnews.com
Submit your review | |